München (ots) - Anmoderationsvorschlag: Für Millionen Deutsche gehören lange Anfahrtswege zum Alltag, ...
Astellas Pharma Europe Ltd. Announces New President of EMEA Operations
Chertsey, England (ots/PRNewswire) - Astellas Pharma Europe Ltd., a subsidiary of Astellas Pharma Inc. (TSE:4503), is pleased to announce that Mr Yukio Matsui has been appointed as President of EMEA Operations, with responsibility for the company's commercial operations in Europe, the Middle East and Africa. Yukio will assume his new position on 1st April 2016. Since April 2015, Yukio has served as Senior Vice President, Head of Marketing Strategy for Astellas' global strategic products.
Commenting on the appointment, Mr Yoshihiko Hatanaka, President and Chief Executive Officer of Astellas Pharma Inc.:
"We expect the strong global performance seen so far in fiscal year 2015 to continue and that the EMEA region will be a key contributor to our sustained growth in the future. The appointment of Yukio Matsui as President of EMEA Operations brings more than 30 years experience to the role - including various important positions in all four regions including Japan, Americas, EMEA, and Asia/Oceania. This experience will be crucial in securing the future success of Astellas for all stakeholders and helping the organisation to stay focused on our vision to be on the forefront of healthcare change to turn innovative science into value for patients."
"I am delighted and honoured to be assuming the role of President of EMEA Operations. Astellas EMEA operates in more than 40 countries across the region and I join at an exciting time with recent launches of a number of innovative medicines and a compelling pipeline in late-stage clinical development for our region. With my international business experiences in both developed countries as well as emerging countries and the combined talents of more than 4,700 colleagues across all the functions in the EMEA region, I am confident we will deliver on the Astellas promise of improving the lives of those patients who depend on our medicines."
Yukio has over 30 years of diverse and international experience in Astellas, including leadership positions as Chief Strategy Officer for EMEA Operations, and Vice President, Marketing & Buiness Management, Asia/Oceania Business. Prior to that, Yukio also held various positions in marketing, sales operations and strategic planning in Japan, the USA, EMEA and Asia.
Yukio succeeds Mr Ken Jones who resigned at the end of February.
Notes to editors
Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritised therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients.
About Astellas Pharma Europe Ltd.
Astellas Pharma Europe Ltd. operates in 40 countries across Europe, the Middle East and Africa, and is the EMEA regional business of Tokyo-based Astellas Pharma Inc (Astellas). Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceuticals. The organisation's focus is to deliver outstanding R&D and marketing to continue growing in the world pharmaceutical market. Astellas' presence in Europe also includes an R&D site and three manufacturing plants. The company employs over 4,700 people across the EMEA region.
Alice Cronshaw Corporate Communications Astellas Pharma EMEA +44
(0)7768 424046 firstname.lastname@example.org